Induction of Combination Therapy for the Management of Hepatitis C: An Observational Study.

hepatitis c interferon rapid virological response ribavirin

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
05 Sep 2020
Historique:
entrez: 12 10 2020
pubmed: 13 10 2020
medline: 13 10 2020
Statut: epublish

Résumé

Background and objective Hepatitis C infection is prevalent in Pakistan. The purpose of this study was to observe the therapeutic effects of conventional interferon in combination with ribavirin among treatment-naive hepatitis C patients. Methods This descriptive cross-sectional study of hepatitis C combination therapy was conducted at our institute after approval. All the patients received treatment with conventional interferon (5-MU three times weekly) and ribavirin (1000mg/day) for four weeks. A follow-up for the rapid virological response (RVR) was done in the fourth week of treatment.  Results The mean age of the patients was 37.43. There was a gradual decrease in RVR with increasing age after four weeks of treatment.  Conclusion The combination therapy showed good RVR in the fourth week among all hepatitis C patients.

Identifiants

pubmed: 33042697
doi: 10.7759/cureus.10259
pmc: PMC7536117
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e10259

Informations de copyright

Copyright © 2020, Khan et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Hepatology. 1997 Jul;26(1):226-31
pubmed: 9214474
Lancet. 1998 Jan 10;351(9096):83-7
pubmed: 9439491
Asian Pac J Trop Med. 2015 Feb;8(2):85-9
pubmed: 25902019
J Virol. 1998 Apr;72(4):2795-805
pubmed: 9525599
Intervirology. 2006;49(1-2):91-5
pubmed: 16166795
Antivir Ther. 2009;14(4):501-11
pubmed: 19578235
Gastroenterology. 1999 Aug;117(2):408-13
pubmed: 10419923
Gut. 2003 Mar;52(3):425-32
pubmed: 12584228
J Hepatol. 2020 Mar;72(3):588-591
pubmed: 31924411
Genes Immun. 2011 Jun;12(4):300-9
pubmed: 21346780
Mol Med Rep. 2017 May;15(5):3336-3339
pubmed: 28339065
Gastroenterology. 2003 Mar;124(3):642-50
pubmed: 12612903
Aliment Pharmacol Ther. 2016 Jun;43(12):1330-9
pubmed: 27091240
J Gastroenterol Hepatol. 2007 Jun;22(6):832-6
pubmed: 17565637

Auteurs

Sultan Z Khan (SZ)

Gastroenterology, Abbottabad International Medical College, Abbottabad, PAK.

Muhammad Umar Talha (MU)

Internal Medicine, District Headquarter Hospital, Gujranwala, PAK.

Bushra Iftikhar (B)

Biochemistry, Azra Nadeed Medical College, Lahore, PAK.

Amina Noor (A)

Internal Medicine, Abbottabad International Medical College, Abbottabad, PAK.

Talha Laique (T)

Pharmacology, Lahore Medical and Dental College, Lahore, PAK.

Aamna Latif (A)

Hematology, Ahmed Medical Complex, Rawalpindi, PAK.

Jahanzeb Malik (J)

Cardiology, Rawalpindi Institute of Cardiology, Rawalpindi, PAK.

Classifications MeSH